AI Stock Memo: TARS - Tarsus - RankAlpha

TARS

AI Memo

Tarsus

As of 2026-01-07/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-01-07 • Model: RankAlpha Sentiment AI

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

Pivotal clinical readout for lead ophthalmic candidate • 2026-09-30

Expected move: +49%

Biggest risk

Bear case assumes clinical setbacks or slower adoption and persistent commercialization headwinds, compressing valuation to ~-30% from anchor.

Invalidation

Break below $56 or thesis failure.

What would change my mind?

Bull case assumes strong clinical readouts, faster-than-expected commercial uptake, and multiple expansion driven by durable reimbursement; market re-rates to ~+25% above anchor.

Research note

Recommendation

—

Confidence

medium

As of

2026-01-07

Base target

$88

p=60%

Bull target

$100

p=20%

Bear target

$56

p=20%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Next quarterly earnings / guidance
Commercial launch and uptake expansion
Bull case assumes strong clinical readouts, faster-than-expected commercial uptake, and multiple expansion driven by durable reimbursement; market re-rates to ~+25% above anchor.

BearKey bullets

Late-stage clinical failure or trial delay
Manufacturing, supply chain, or regulatory setbacks
Weak XDEMVY uptake or payer reimbursement resistance

WatchKey bullets

Pivotal clinical readout for lead ophthalmic candidate

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $88 (p=60%)

Bull/Bear spread: +69% / -5%

Vs latest close: Bull +69% · Base +49% · Bear -5%

Scenario probabilities

Bull Target: $100 (p=20%)Base Target: $88 (p=60%)Bear Target: $56 (p=20%)

Commentary

Consensus targets cluster in the mid-$80s; the base case implies modest upside versus the anchor. Market tone is cautiously constructive—commercial execution and recent sales support upside, while insider selling and binary clinical outcomes keep near-term sentiment fragile. Key near-term drivers: earnings/guidance and clinical readouts.

As of 2026-01-07 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bull case assumes strong clinical readouts, faster-than-expected commercial uptake, and multiple expansion driven by durable reimbursement; market re-rates to ~+25% above anchor.

Bear Case

Bear case assumes clinical setbacks or slower adoption and persistent commercialization headwinds, compressing valuation to ~-30% from anchor.

Drivers

Scannable catalysts and supporting factors

Next quarterly earnings / guidance
Commercial launch and uptake expansion

Human Analyst Targets

External snippets for comparison only; verify at source.

Unverified externalLast fetched 2026-01-07Source quality: external scrape

External snippets are unverified; treat as directional signals only. Always confirm with the original provider.

Inline RA est

Provider

serper

Median (USD)

$84.42

Range (USD)

$51.00 - $105.00

Count

Query: Tarsus Pharmaceuticals Inc Common (TARS) analyst consensus price target high low average

Tarsus Pharmaceuticals Inc (TARS) Stock Forecast & Price Target
Search result #1
According to projections from 10 analysts, the average 12-month price target for Tarsus is 87.5, with a high estimate of 100 and a low estimate of 51. What Is ...
Open source
Tarsus Pharmaceuticals, Inc. (TARS) Price Targets
Search result #2
The forecasts for Tarsus Pharmaceuticals, Inc. (TARS) range from a low of $51 to a high of $100. The average price target represents a increase of $8.82 from ...
Extracted: $51.00, $100.00, $8.82Open source
Tarsus Pharmaceuticals (TARS) Stock Forecast and Price Target 2026
Search result #3
According to the 9 analysts' twelve-month price targets for Tarsus Pharmaceuticals, the average price target is $79.86. The highest price target for TARS is ...
Extracted: $79.86Open source
TARS | Tarsus Pharmaceuticals Inc. Analyst Estimates - MarketWatch
Search result #4
1.75. Median PE on Next FY Estimate, N/A. Stock Price Targets. High, $100.00. Median, $88.00. Low, $51.00. Average, $87.50. Current Price, $81.88. Yearly ...
Extracted: $100.00, $88.00, $51.00, $87.50, $81.88Open source
Tarsus Pharmaceuticals, Inc. (TARS) Analyst Ratings, Estimates ...
Search result #5
See Tarsus Pharmaceuticals, Inc. (TARS) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades.
Open source
TARS / Tarsus Pharmaceuticals, Inc. (NasdaqGS) - Forecast, Price ...
Search result #6
The average one-year price target for Tarsus Pharmaceuticals, Inc. is $86.96. The forecasts range from a low of $51.51 to a high of $105.00. Read More.
Extracted: $86.96, $51.51, $105.00Open source

Scenarios

Bull Target (Scenario probability)

$100 / p=20% prob

Base Target (Scenario probability)

$88 / p=60% prob

Bear Target (Scenario probability)

$56 / p=20% prob

Price $59 as of 2026-07-31

Nearest Scenario: Bear (∆ 5%)

Targets vs latest close: Bull +69% · Base +49% · Bear -5%

Sentiment & Exposure

Sentiment unavailable: insufficient coverage

Events

Other notable items detected

EVENT2026-09-30
Pivotal clinical readout for lead ophthalmic candidate
A positive Phase 3 readout would materially re-rate valuation; timeline uncertain so using a conservative assumed window end for planning purposes (assumed end of Sept 2026) [#SERP-3].
Prob 45.00% • Move 60.00% • Priced-in 20.00%

Short-term Catalysts

Next few weeks

Next quarterly earnings / guidance
2026-04-07
Upcoming quarterly results and management guidance can drive near-term sentiment; analysts' 12-month targets show dispersion around the anchor, which may amplify moves on surprise results [#SERP-1].
Prob 75% • Move 12% • Priced-in 40%

Long-term Catalysts

Months to a year

Commercial launch and uptake expansion
2027-01-07
Wider commercial rollout and reimbursement progress would support longer-term multiple expansion; gradual realization expected over the next year [#SERP-2].
Prob 55% • Move 35% • Priced-in 15%

Risks

Late-stage clinical failure or trial delay
Manufacturing, supply chain, or regulatory setbacks
Weak XDEMVY uptake or payer reimbursement resistance

Peers

Symbol	Summary
OCUL	Small-cap ophthalmic therapeutics with similar development/commercialization profile and execution risk.
FGEN	Biotech peer with niche therapeutic focus; useful comparator for development-stage commercialization dynamics.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment AI
Human targets: serper
Targets query: Tarsus Pharmaceuticals Inc Common (TARS) analyst consensus price target high low average
Analysis date: 2026-01-07